Comparative Assessment of the Safety between Pazopanib and Sunitinib for Metastatic Renal Cell Carcinoma
DOI:
https://doi.org/10.21776/ub.jkb.2022.032.02.4%20Keywords:
Metastatic renal cell carcinoma, pazopanib, safety, sunitinibAbstract
Renal cell carcinoma (RCC) is the most common kidney lesion with approximately 90% of all kidney malignancies and 30% of people with RCC have developed metastasis at the time of diagnosis. Based on European Association of Urology (EAU) guideline, therapy for metastatic RCC (mRCC) patient who cannot tolerate immune checkpoint inhibitor is pazopanib or sunitinib. However, these drugs cause several uncomfortable side effects for the patient. Therefore, this meta-analysis was made, based on the available evidence base, to compare the safety of pazopanib and sunitinib as the treatment of mRCC. Systematic reviews were made in accordance with the PRISMA guideline requirements, a literature review was conducted in January 2022 used PubMed, ScienceDirect, Cochrane Library, publishing year of at least 10 years with an adult population. And the data is analyzed using RevMan V.5.4. In total 1.665 participants, there were 431 patients taking pazopanib and 1.234 patients taking sunitinib from 8 studies. The result shows that sunitinib has more frequent result of side effects than pazopanib in several occasion like hand-foot syndrome, nausea/vomiting, skin rash, stomatitis & mucosal inflammation, leucopenia and thrombocytopenia. Meanwhile, there are no significant differences between pazopanib and sunitinib in causing other side effect such as fatigue, diarrhea, hypertension, anemia, and increased liver enzymes. The conclusion is that pazopanib is better and has less frequent side effects than sunitinib.
Downloads
References
B Ljungberg, L Albiges, J Bedke, A Bex, et al. Guideline on Renal Cell Carcinoma 2021. (Online) 2021. https://uroweb.org/guideline/renal-cell-carcinoma/ [accessed 10 January 2022]
Kim JH, Park I, and Lee JL. Pazopanib Versus Sunitinib for the Treatment of Metastatic Renal Cell Carcinoma Patients with Poor-Risk Features. Cancer Chemotherapy and Pharmacology. 2016; 78(2): 325–332.
Uccello M, Alam T, Abbas H, Nair A, Paskins J, and Faust G. Assessing Outcomes and Prognostic Factors for First-Line Therapy in Elderly Patients with Metastatic Renal Cell Carcinoma: Real-Life Data from a Single United Kingdom Institution. Clinical Genitourinary Cancer. 2019; 17(3): e658–e663.
Moher D, Liberati A, Tetzlaff J, Altman DG, and PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Medicine. 2009; 6(7): 336-341.
Wells G, Shea BJ, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. (Online) 2021. http://www.ohri.ca/programs/clinical_ epidemiology/oxford.asp [accessed 21 February 2022].
Phillips B, Ball C, Sackett D, et al. Oxford Centre for Evidence-Based Medicine— Levels Of Evidence. (Online) 2009. https://www.cebm.ox.ac.uk/ resources/levels-of-evidence/oxford-centre-for-evidence-based-medicine-levels-of-evidence-march-2009 [accessed 21 February 2022].
Ekenel M, Karabulut S, Cil I, Zırtıloglu A, Aydın E, and Tural D. Sunitinib Versus Pazopanib for Patients with Metastatic Renal Cell Carcinoma: 2 Turkish Hospital Experience. 2020; 44(1): 27–33.
Hirsch BR, Harrison MR, George DJ, et al. Use of "Real-World" Data to Describe Adverse Events During the Treatment of Metastatic Renal Cell Carcinoma in Routine Clinical Practice. Medical Oncology. 2014; 31(9): 1-8.
Lalani AA, Li H, Heng DYC, et al. First-Line Sunitinib or Pazopanib in Metastatic Renal Cell Carcinoma: The Canadian Experience. Canadian Urological Association Journal. 2017; 11(3-4): 112–117.
Pierantoni F, Basso U, Maruzzo M, et al. Comprehensive Geriatric Assessment is an Independent Prognostic Factor in Older Patients with Metastatic Renal Cell Cancer Treated with First-Line Sunitinib or Pazopanib: A Single Center Experience. Journal of Geriatric Oncology. 2021; 12(2): 290–297.
Rudresha AH, Chaudhuri T, Lakshmaiah KC, et al. First-Line Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma: A Regional Cancer Center Experience. Indian Journal of Cancer. 2017; 54(4): 626–630.
Yuan A, Kurtz SL, Barysauskas CM, Pilotte AP, Wagner AJ, and Treister NS. Oral Adverse Events in Cancer Patients Treated with VEGFR-Directed Multitargeted Tyrosine Kinase Inhibitors. Oral Oncology. 2015; 51(11): 1026–1033.
Schutz FA, Choueiri TK, and Sternberg CN. Pazopanib: Clinical Development of a Potent Anti-Angiogenic Drug. Critical Reviews in Oncology/Hematology. 2011; 77(3): 163–171.
Escudier B, Porta C, Bono P, et al. Randomized, Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients with Metastatic Renal Cell Carcinoma: PISCES Study. Journal of Clinical Oncology. 2014; 32(14): 1412–1418.
Motzer RJ, Hutson TE, Cella D, et al. Pazopanib Versus Sunitinib in Metastatic Renal-Cell Carcinoma. The New England Journal of Medicine. 2013; 369(8): 722–731.
Delea TE, Amdahl J, Diaz J, Nakhaipour HR, and Hackshaw MD. Cost-Effectiveness of Pazopanib Versus Sunitinib for Renal Cancer in the United States. Journal of Managed Care & Specialty Pharmacy. 2015; 21(1): 46-54.
Amdahl J, Diaz J, Sharma A, Park J, Chandiwana D, and Delea TE. Cost-Effectiveness of Pazopanib Versus Sunitinib for Metastatic Renal Cell Carcinoma in the United Kingdom. PloS One. 2017; 12(6): 1-18.
Amdahl J, Diaz J, Park J, Nakhaipour HR, and Delea TE. Cost-Effectiveness of Pazopanib Compared with Sunitinib in Metastatic Renal Cell Carcinoma in Canada. Current Oncology. 2016; 23(4): e340–e354.
Capri S, Porta C, Condorelli C, et al. An Updated Cost-Effectiveness Analysis of Pazopanib Versus Sunitinib as First-Line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma in Italy. Journal of Medical Economics. 2020; 23(12): 1579–1587.
Deng H, Huang Y, Hong Z, et al. Pazopanib Has Equivalent Anti-Tumor Effectiveness and Lower Total Costs than Sunitinib for Treating Metastatic or Advanced Renal Cell Carcinoma: A Meta-Analysis. BMC Cancer. 2019; 19: 1-12.
Vogelzang NJ, Pal SK, Ghate SR, Li N, et al. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data. Journal of Managed Care & Specialty Pharmacy. 2018; 24(6): 525–533.
Hansen RN, Hackshaw MD, Nagar SP, et al. Health Care Costs among Renal Cancer Patients Using Pazopanib and Sunitinib. Journal of Managed Care & Specialty Pharmacy. 2015; 21(1): 37–44.
Li W, Feng C, Di W, et al. Clinical Use of Vascular Endothelial Growth Factor Receptor Inhibitors for the Treatment of Renal Cell Carcinoma. European Journal of Medicinal Chemistry. 2020; 2020: 1-9.
Downloads
Published
Versions
- 2022-11-21 (3)
- 2022-11-04 (2)
- 2022-08-31 (1)
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
